Sandoz Sues To Invalidate Prostate Cancer Drug Patent
Generic drugmaker Sandoz AG is suing to invalidate a patent for a prostate cancer drug similar to that sold by Astellas Pharma Inc. under the brand name Xtandi, claiming that the...To view the full article, register now.
Already a subscriber? Click here to view full article